Please assess the completion status of the following clinical trial:

Trial Title: Autologous Mesenchymal Stem Cell Transplant for Parkinson's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* Male or female between 35-70 years of age.~* Patient with current diagnosis of PD with motor complications (as confirmed by neurologist) as per the standard criteria and guidelines.~* Patients with at least 5 years since the disease.~* Responsiveness to Levodopa or dopa agonist. This is defined as improvement between Off and On UPDRS by at least 33% of the Motor UPDRS.~* PD of Stage 2.5, 3 \& 4 of HOEHN \& YAHR staging.~* Stable Parkinsonian medications for the 60 days prior to the surgical therapy.~* MRI not showing gross atrophy or any other pathology of brain.~* Patients with score less than 19 for the Montgomery-Asberg Rating Scale (MADRS) for Depression.~* NO Significant cognitive impairment.MMSE \> 24.~* The participant is able to comply with and understand the required visit schedule and all required tests and procedures.~* The participant (and/or LAR) must sign an informed consent.~Exclusion Criteria:~* History of intracranial surgeries or implantation of a device for Parkinson's disease two years prior to treatment.~* History of psychiatric disorders like schizophrenia or psychotic disorders.~* History of other malignancy, with the exception of treated cutaneous squamous cell or basal cell carcinoma, within 5 years.~* Contraindication for MRI~* General medical contraindications for surgery like coagulopathy~* Subjects with abnormal hematology and chemistry values, unless the out of range values are clinically significant with respect to general surgery.~* Severe skin infection or osteomyelitis at the site of bone marrow aspiration potentially limiting the procedure.~* Positive test results for HIV.~* History of drug or alcohol abuse~* Pregnant or nursing women

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Therapy for Parkinson's disease (Type: EXPERIMENTAL): Stem cell derived from the bone marrow of the patient will be stereotactically transplanted in the striatum.These stem cell are the expected to grow up into dopamine secreting neural cells.

Based on this trial design, predict the completion outcome and termination type (if applicable).